HIRN Consortium on Targeting and Regeneration (HIRN-CTAR)(RFA-DK-22-009)

HIRN Consortium on Targeting and Regeneration (HIRN-CTAR) (RFA-DK-22-009)

Purpose: This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN). Learn more HERE.

Deadlines:
Letter of Intent: September 22, 2022
Application: October 26, 2022
Earliest Start Date: July 2023

Follow
×

Follow

us on our social networks.